Interferon-free therapies for hep C virus look promising

Interferon-free therapies for hep C virus look promising
For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease inhibitor ABT-450, combined with low-dose ritonavir plus the nonnucleoside NS5B polymerase inhibitor ABT-333 and ribavirin, seems effective for genotype 1, according to two studies published in the Jan. 2 issue of the New England Journal of Medicine.

(HealthDay)—For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease inhibitor ABT-450, combined with low-dose ritonavir (ABT-450/r) plus the nonnucleoside NS5B polymerase inhibitor ABT-333 and ribavirin, seems effective for genotype 1, according to two studies published in the Jan. 2 issue of the New England Journal of Medicine.

Edward J. Gane, M.D., from Auckland City Hospital in New Zealand, and colleagues evaluated sofosbuvir in interferon-sparing and interferon-free regimens for patients with untreated HCV genotype 2 and 3. After 24 weeks of therapy, the researchers found that all patients who received sofosbuvir plus ribavirin without interferon or with interferon had a sustained virologic response. In addition, 84 percent of previously untreated patients with HCV genotype 1 had a sustained virologic response with sofosbuvir and ribavirin.

In a second study, Fred Poordad, M.D., from the University of Texas Health Science Center in San Antonio, and colleagues assessed the role of ABT-450/r, ABT-333, and ribavirin for treatment of HCV 1 infection without cirrhosis in a 12-week phase 2a study. The researchers found that most untreated patients had an extended rapid virologic response, and 93 to 95 percent had a sustained virologic response 12 weeks after the end of treatment. Forty-seven percent of those who had had a null or partial response to previous therapy with peginterferon and ribavirin had sustained 12 weeks after therapy.

"This preliminary study suggests that 12 weeks of therapy with a combination of a , a nonnucleoside polymerase inhibitor, and ribavirin may be effective for treatment of HCV genotype 1 infection," Poordad and colleagues conclude.

The Gane study was supported by Pharmasset and Gilead Sciences; the Poordad study was funded by Abbott.

More information: Full Text - Gane (subscription or payment may be required)
Full Text - Poordad (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Coffee drinking improves hepatitis C treatment response

Jun 07, 2011

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) ...

Recommended for you

Mali announces new Ebola case

2 hours ago

Mali announced Saturday a new case of Ebola in a man who is fighting for his life in an intensive care unit in the capital Bamako.

Plague outbreak kills 40 in Madagascar: WHO

2 hours ago

An outbreak of plague has killed 40 people in Madagascar, the World Health Organization said, warning that the disease could spread rapidly in the country's densely populated capital Antananarivo.

UN chief: Ebola cases in Mali a 'deep concern'

16 hours ago

The United Nations chief warned Friday that Ebola may be easing in part of West Africa but is still hitting hard in other areas and outpacing the international response.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.